Major share increase and equity plan votes ahead for Palisade Bio (NASDAQ: PALI)
Palisade Bio (NASDAQ: PALI) is requesting stockholder approval for several key proposals at its virtual 2026 annual meeting on June 10, 2026. These proposals include increasing authorized common stock from 300,000,000 to 450,000,000 shares, approving amended equity incentive and employee stock purchase plans (removing evergreen features), electing directors, and ratifying their auditor. The changes aim to enhance financial flexibility, align executive and director incentives with stockholder interests, and secure future compensation and financing needs.
APR 1·Moomoo▼
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease
This article reports on Palisade Bio's stock performance following the release of Phase 1b data for PALI-2108 in patients with fibrostenotic Crohn's disease. The data indicated that three of five subjects experienced adverse events which were considered treatment-related, leading to a decline in the company's shares. Despite this, the clinical trial will continue into a multi-dose portion, exploring different dosing strategies.
MAR 31·Stock Titan▲
After 2 weeks, Palisade’s Crohn’s pill showed no serious side effects
Palisade Bio reported positive topline Phase 1b data for its Crohn's disease drug, PALI-2108, which demonstrated favorable safety and tolerability with no serious adverse events over a 14-day study period. The drug showed significant endoscopic improvements, including a 47.5% reduction in SES-CD scores and a 40% endoscopic response and remission rate. The company plans to advance PALI-2108 into a Phase 2 trial for moderate-to-severe Crohn’s disease, aiming to assess anti-fibrotic effects and further validate its potential as a targeted therapy.
